Pankaj Singh currently develops content for healthcaremotives.com and numerous other news portals. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his profession. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605
The positive result positions the company well on delivering its strategic goals for 2019 and encourages the company to expand its evaluation efforts. BioSig Technologies, Inc., a US-based medical device company, recently announced that it has successfully conducted the first in-human cases using PURE EPTM System which is a proprietary …
QIAGEN can use Ares Genetics’ Antimicrobial Resistance (AMR) database and use its expertise in bioinformatics to accelerate AMR research. QIAGEN N.V., the Netherlands-based provider of Sample to Insight solutions recently announced that it has signed a broad agreement with Ares Genetics that specializes in infectious disease diagnostics and therapeutics, to …
The company wants to establish a global leader in tumor precision medicine brand and also lead China’s cancer genetic testing industry. Chinese biotech company Burning Rock has reportedly completed a $125.5 million (850 million yuan) Series C funding round which was led by GIC, the sovereign wealth fund of Singapore. …
The clinical study is meant to evaluate the primary efficacy, tolerance and safety of IBI101. Innovent Biologics, Inc., a China based, global biopharmaceutical company that specializes in development, manufacturing and commercialization of superior quality innovative medicines for cancer, immunotherapy and other diseases, recently announced that it will be initiating its …
The safety profile of DARZALEX was unchanged in case of a split or single initial dose and there were no safety events in case of the split-dosage regimen. The Janssen Pharmaceutica recently announced that it has received approval from the U.S. Food and Drug Administration for split-dosage regimen of DARZALEX®(daratumumab). …
The deal is to be renewed every two years after its initial five-year term and will continue thus until cancelled. WuXi Biologics, a leader in biologics discovery, development and manufacturing offering open-access biologics technology recently announced that it has entered into an exclusive manufacturing partnership with Amicus Therapeutics, a biotechnology …
The agreement showcases the interest of prominent orthobiologic firms in Kuros technologies. The global partner would be responsible for marketing an advanced bone graft that would be supplied by Kuros. Kuros Biosciences (Kuros), a renowned Swiss biotechnology company, has reportedly announced that the company’s Dutch subsidiary has entered into an Original …
Precision for Medicine has announced the acquisition of ApoCell, a Houston-based next-generation lab that specializes in the identification and analysis of biomarkers. By acquiring ApoCell, its ApoStream® liquid biopsy technology and extensive tissue profiling expertise will be added to Precision’s strong portfolio of specialty laboratory and biomarker informatics services. The …
The Basel headquartered healthcare company Roche Holding AG has globally launched three next-generation sequencing AVENIO Tumor Tissue Analysis Kits for use in oncology research. The new AVENIO Tumor Tissue Targeted Kit, Surveillance Kit and Expanded Kit help to detect all four mutation classes in solid tumors and compliment Roche’s NGS …
The U.S. based pharmaceutical firm Eli Lilly and Company has reportedly announced to have forayed in the autoimmune segment in India. As per trusted sources, the drug maker has launched a new once-daily oral therapy, named as Olumiant, to treat rheumatoid arthritis. Reportedly, OlumiantTM is an advanced and effective once-daily …
